Globeflex Capital L P Has $4.07 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Globeflex Capital L P grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 319.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 194,786 shares of the biopharmaceutical company’s stock after buying an additional 148,388 shares during the period. Globeflex Capital L P owned 0.16% of Catalyst Pharmaceuticals worth $4,065,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after buying an additional 151,495 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock valued at $26,023,000 after buying an additional 79,182 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its position in shares of Catalyst Pharmaceuticals by 74.3% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock worth $15,421,000 after purchasing an additional 312,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company’s stock worth $15,100,000 after purchasing an additional 9,194 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Catalyst Pharmaceuticals by 4.3% in the 4th quarter. Principal Financial Group Inc. now owns 600,488 shares of the biopharmaceutical company’s stock worth $12,532,000 after purchasing an additional 24,535 shares during the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $21.02 on Friday. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 17.81, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock’s 50-day moving average is $22.26 and its 200-day moving average is $21.52. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on CPRX shares. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens restated an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America restated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $32.50.

Insider Activity

In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.